Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from InMed Pharmaceuticals ( (INM) ) is now available.
InMed Pharmaceuticals held a special meeting on June 13, 2025, to approve a potential issuance of more than 20% of its common shares, as per Nasdaq rules. However, due to the lack of a quorum, no business was conducted, and the board is considering whether to reschedule the meeting or address the proposal at the annual general meeting.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
InMed Pharmaceuticals shows significant financial challenges with persistent losses and negative cash flows, which heavily weigh down its score. The stock’s technical indicators reflect short-term positive momentum, offering some optimism amid volatility. The valuation remains constrained by ongoing losses and lack of profitability metrics, typical for the biotechnology sector.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
Average Trading Volume: 1,321,589
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.08M
For a thorough assessment of INM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue